What’s Next for Cell and Gene Therapies in 2023 and Beyond

This workshop will feature leading executives in the ATMP space who will discuss a number of topics including future technologies, the current investment environment and what innovators can do to mitigate growing market pressures. The session will also touch upon resolving manufacturing and regulatory bottlenecks as the sector moves towards commercialization, as well as the evolution of reimbursement payment models.

Chair:
Anshul Mangal, President, Precision ADVANCE and Project Farma

Speakers:
Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone Biologics
Andrew Knudten, Chief Operating Officer, Jaguar Gene Therapy
Laura Lande-Diner, Ph.D., Chief Business Officer, Satellite Bio
Robert Peters, Ph.D., Chief Scientific Officer, Ensoma
Deb Phippard, Ph.D., Chief Scientific Officer, Precision for Medicine